Drug delivery via lipoprotein-based carriers: Answering the challenges in systemic therapeutics

Therapeutic Delivery

Volumn 3, Issue 5, 2012, Pages 599-608

  Sabnis, Nirupama ^a   Lacko, Andras G ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CYTOTOXIC AGENT; DOXORUBICIN; DRUG CARRIER; FLUOROURACIL; HIGH DENSITY LIPOPROTEIN NANOCARRIER; IDOXURIDINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NANOSTRUCTURED LIPID CARRIER; RECOMBINANT APOLIPOPROTEIN A1; RECOMBINANT HIGH DENSITY LIPOPROTEIN; RECOMBINANT PROTEIN; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; VALRUBICIN; VINDESINE;

ALZHEIMER DISEASE; BIOCOMPATIBILITY; CANCER CELL; CANCER CHEMOTHERAPY; COMPLEX FORMATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; EMBOLIC STROKE; HEPATITIS B; HUMAN; LEISHMANIASIS; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PERSONALIZED MEDICINE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; STROKE;

EID: 84861316480     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.41     Document Type: Review

References (81)

1. Petkar KC, Chavhan SS, Agatonovik- Kustrin S, Sawant KK. Nanostructured materials in drug and gene delivery: a review of the state of the art. Crit. Rev. Ther. Drug Carrier Syst. 28(2), 101-164 (2011).
2. Chakraborty M, Jain S and Rani V. Nanotechnology: emerging tool for diagnostics and therapeutics. Appl. Biochem. Biotechnol. 165(5-6), 1178-1187 (2011).
3. Ma X, Zhao Y, Liang XJ. Theranostic nanoparticles engineered for clinic and pharmaceutics. Acc. Chem. Res. 44(10), 1114-1122 (2011).
4. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomed. 3(2), 133-149 (2008).
5. Ward CS, Venkatesh HS, Chaumeil MM et al. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res. 70(4), 1296-1305 (2010).
6. Lewis DR, Kamisoglu K, York AW, Moghe PV. Polymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosis. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3(4), 400-420 (2011).
7. Chekman IS, Ulberg ZR, Gorchakova NO et al. The prospects of medical application of metal-basednanoparticles and nanomaterials. Lik. Sprava. 1-2, 3-21 (2011).
8. Kaminskas LM, Porter CJ. Targeting the lymphatics using dendritic polymers (dendrimers). Adv. Drug Deliv. Rev. 63(10-11), 890-900 (2011).
9. Chen F, Zhu YJ, Zhang KH et al. Europium-doped amorphous calcium phosphate porous nanospheres: preparation and application as luminescent drug carriers. Nanoscale Res. Lett. 6(1), 67 (2011
10. Liu H, Webster TJ. Mechanical properties of dispersed ceramic nanoparticles in polymer composites for orthopedic applications. Int. J. Nanomed. 5, 299-313 (2010).
11. Waiczies H, Lepore S, Janitzek N et al. Perfluorocarbon particle size influences magnetic resonance signal and immunological properties of dendritic cells. PLoS One 6(7), 21981-21990 (2011).
12. Kempe M, Kempe H, Snowball I et al. The use of magnetite nanoparticles for implant-assisted magnetic drug targeting in thrombolytic therapy. Biomaterials 31(36), 9499-9510 (2010).
13. Maysinger D, Lovric J. Quantum dots and other fluorescent nanoparticles: quo vadis in the cell? Adv. Exp. Med. Biol. 620, 156-167 (2007).
14. Lacko AG, Nair M, Prokai L, McConathy WJ. Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Exp. Opin. Drug Deliv. 4(6), 665-675 (2007).
15. Ng KK, Lovell JF, Zheng G. Lipoprotein-inspired nanoparticles for cancer theranostics. Acc. Chem. Res. 44(10), 1105-1113 (2011).
16. Elnaggar YS, El-Massik MA, Abdallah OY. Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipidnanoparticles. Int. J. Nanomed. 6, 3195-3205 (2011).
17. Wang JJ, Zeng ZW, Xiao RZ et al. Recent advances of chitosannanoparticles as drug carriers. Int. J. Nanomed. 6, 765-774 (2011).
18. Spuch C, Navarro C. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimers disease and Parkinsons disease). J. Drug Deliv. doi:10.1155/2011/469679 (2011).
19. Attama AA. SLN, NLC, LDC: state of the art in drug and active delivery. Recent Pat. Drug Deliv. Formul. 5(3), 178-187 (2011).
20. Shahzad MM, Mangala LS, Han HD et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 13(4), 309-319 (2011).
21. Zheng G, Chen J, Li H, Glickson JD. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc. Natl Acad. Sci. USA 102(49), 17757-17762 (2005).
22. Mooberry LK, Nair M, Paranjape S, McConathy WJ, Lacko AG. Receptor-mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J. Drug Target. 18(1), 53-58 (2010).
23. Sabnis N, Nair M, Israel M, Walter J, McConathy WJ, Lacko AG. Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int. J. Nanomed. 7, 1-9 (2012).
24. McConathy WJ, Nair MP, Paranjape S, Mooberry L, Lacko AG. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs 19(2), 183-188 (2008).
25. Gotto AM, Pownall HJ, Havel RJ. Introduction to the plasma lipoproteins. Methods Enzymol. 128, 3-41 (1986).
26. Chapman MJ. Animal lipoproteins: chemistry, structure, and comparative aspects. J. Lipid Res. 21(7), 789-853 (1980).
27. Bricarello DA, Smilowitz JT, Zivkovic AM, German JB, Parikh AN. Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures. ACS Nano. 5(1), 42-57 (2011).
28. Pluen A, Boucher Y, Ramanujan S et al. Role of tumor host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc. Natl Acad. Sci. USA 98(8), 4628-4633 (2001).
29. Thomas M, Bhat S, Sorci-Thomas M. Three-dimensional models of HDL APOA-I. Implications for its assembly and function. J. Lipid Res. 49(9), 1875-1883 (2008).
30. Denisov I, Grinkova Y, Lazarides A, Sligar S. Directed self-assembly of monodisperse phospholipid bilayer nanodiscs with controlled size. J. Am. Chem. Soc. 126(11), 3477-3487 (2004).
31. Chen J, Corbin IR, Li H, Cao W, Glickson JD, Zheng G. Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo. J. Am. Chem. Soc. 129(18), 5798-5798 (2007).
32. Tatarczyk T, Ciardi C, Niederwanger A, Kranebitter M, Patsch JR, Pedrini MT. Postprandial triglyceride-rich lipoproteins induce hepatic insulin resistance in HepG2 cells independently of their receptor-mediated cellular uptake. Mol. Cell Endocrinol. 343(1-2), 71-78 (2011).
33. McConathy WJ, Paranjape S, Mooberry L et al. Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF). Drug Deliv. Transl. Res. 1(2), 113-120 (2011).
34. Krieger M, Smith LC, Anderson RG et al. Reconstituted low density lipoprotein: a vehicle for the delivery of hydrophobic fluorescent probes to cells. J. Supramol. Struct. 10(4), 467-478 (1979).
35. Gal D, Macdonald PC, Porter JC, Simpson ER. Cholesterol metabolism in cancer cells in monolayer culture. III. Low-density lipoprotein metabolism. Int. J. Cancer 28(3), 315-319 (1981).
36. Kader A, Pater AJ. Loading anticancer drugs into HDL as well as LDL has little effect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J. Control. Rel. 80(1-3), 29-44 (2002).
37. Ponty E, Favre G, Benaniba R et al. Biodistribution study of 99mTc-labeled LDL in B16-melanoma-bearing mice: visualization of a preferential uptake by the tumor. Int. J. Cancer 54(11), 411-417 (1993).
38. Corbin IR, Li H, Chen J et al. Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. Neoplasia 8(6), 488-498 (2006).
39. De Smidt PC, Van Berkel TJ. LDL-mediated drug targeting. Crit. Rev. Ther. Drug Carrier Syst. 7(2), 99-120(1990).
40. Vitols S, Angelin B, Ericsson S et al. Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc. Natl Acad. Sci. USA 87(7), 2598-2602 (1990).
41. Dorlhiac-Llacer PE, Marquezini MV, Toffoletto O, Carneiro RC, Maranhão RC, Chamone DA. In vitro cytotoxicity of the LDE: daunorubicin complex in acute myelogenous leukemia blast cells. Braz. J. Med. Biol. Res. 34(10), 1257-1263 (2001).
42. Ahotupa M, Suomela JP, Vuorimaa T, Vasankari T. Lipoprotein-specific transport of circulating lipid peroxides. Annu. Med. 42(7), 521-529 (2010).
43. Meng QH, Wähälä K, Adlercreutz H, Tikkanen MJ. Antiproliferative efficacy of lipophilic soy isoflavone phytoestrogens delivered by low density lipoprotein particles into cultured U937 cells. Life Sci. 65(16), 1695-1705 (1999).
44. Lestavel-Delattre S, Martin-Nizard F, Clavey V et al. Low-density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells. Cancer Res. 52(13), 3629-3635 (1992).
45. Hu J, Liu H, Wang L. Enhanced delivery of AZT to macrophages via acetylated LDL. J. Control. Rel. 69(3), 327-335 (2000).
46. Jin H, Lovell JF, Chen J et al. Cytosolic delivery of LDL nanoparticle cargo using photochemical internalization. Photochem. Photobiol. Sci. 10(5), 810-816 (2011).
47. Crich SG, Lanzardo S, Alberti D et al. Magnetic resonance imaging detection of tumor cells by targeting low-density lipoprotein receptors with Gd-loaded low-density lipoprotein particles. Neoplasia 9(12), 1046-1056 (2007).
48. Owens MD, Baillie G, Halbert GW. Physicochemical properties of microemulsion analogues of low density lipoprotein containing amphiphatic apoprotein B receptor sequences. Int. J. Pharm. 228(1-2), 109-117 (2001).
49. Shaw JM, Shaw KV. Key issues in the delivery of pharmacological agents using lipoproteins: design of a synthetic apoprotein-lipid carrier. Target. Diagn. Ther. 5, 351-383 (1991).
50. de Smidt PC, Versluis AJ, van Berkel TJ. Properties of incorporation, redistribution, and integrity of porphyrin-low-density lipoprotein complexes. Biochemistry 32(11), 2916-2922 (1993).
51. Masquelier M, Vitols S, Palsson M, Mars U, Larsson BS, Peterson C. Low density lipoprotein as a carrier of cytostatics in cancer chemotherapy: study of stability of drug-carrier complexes in blood. J. Drug Target. 8(3), 155-164 (2000).
52. Clayman RV, Bilhartz LE, Spady DK, Buja LM, Dietschy JM. Low density lipoprotein-receptor activity is lost in vivo in malignantly transformed renal tissue. FEBS Lett. 196(1), 87-90 (1986).
53. Fabricant M, Broitman SA. Evidence for deficiency of low density lipoprotein receptor on human colonic carcinoma cell lines. Cancer Res. 50(3), 632-636 (1990).
54. Tatidis L, Masquelier M, Vitols S. Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines. Biochem. Pharmacol. 63(12), 2169-2180 (2002).
55. Glomset JA. The plasma lecithins: cholesterol acyltransferase reaction. J. Lipid Res. 9(2), 155-167 (1968).
56. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271(5248), 518-520 (1996).
57. Leon CG, Locke JA, Adomat HH et al. Alterations in cholesterol regulation contribute to the production of intra tumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 70(4), 390-400 (2010).
58. Kader A, Pater AJ. Loading anticancer drugs into HDL as well as LDL has little effect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J. Control. Rel. 80(1-3), 29-44 (2002).
59. Lou B, Liao XL, Wu MP, Cheng PF, Yin CY, Fei Z. High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J. Gastroenterol. 11(7), 954-959 (2005).
60. Zhang WL, Xiao Y, Liu JP et al. Structure and remodeling behavior of drug-loaded high density lipoproteins and their atherosclerotic plaque targeting mechanism in foam cell model. Int. J. Pharm. 419(1-2), 314-321 (2011).
61. Cho KH. Enhanced delivery of rapamycin by V156K-ApoA-I high-density lipoprotein inhibits cellular proatherogenic effects and senescence and promotes tissue regeneration. J. Gerontol. A Biol. Sci. Med. Sci. 66(12), 1274-1285 (2011).
62. Shiflett AM, Bishop JR, Pahwa A, Hajduk SL. Human high density lipoproteins are platforms for the assembly of multicomponent innate immune complexes. J. Biol. Chem. 280, 32578-32585 (2005).
63. Feng M, Cai Q, Shi X et al. Recombinant high-density lipoprotein complex as a targeting system of nosiheptide to liver cells. J. Drug Target. 16(6), 502-508 (2008).
64. Bhattacharya P, Grimme S, Ganesh B et al. Nanodisc-incorporated hemagglutinin provides protective immunity against influenza virus infection. J. Virol. 84, 361-371 (2010).
65. de Vrueh, RL, Rump ET, van De Bilt E et al. Carrier-mediated delivery of 9-(2-phosphonylmethoxyethyl) adenine to parenchymal liver cells: a novel therapeutic approach for hepatitis B. Antimicrob. Agents Chemother. 44(3), 477-483 (2000).
66. Nelson K, Bishop J, Ryan R, Titus R. Nanodisk-associated amphotericin B clears leishmania major cutaneous infection in susceptible BALB/C mice. Antimicrob. Agents Chemother. 50(4), 1238-1244 (2006).
67. Handattu S, Garber D, Monroe C et al. Oral apolipoprotein AI mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimers disease. Neurobiol. Dis. 34(3), 525-534 (2009).
68. Paula-Lima AC, Tricerri MA, Brito-Moreira J et al. Human apolipoprotein A-I binds amyloid-[b] and prevents a[b]-induced neurotoxicity. Int. J. Biochem. Cell Biol. 41, 1361-1370 (2009).
69. Balazs Z, Panzenboeck U, Hammer A et al. Uptake and transport of high density lipoprotein (HDL) and HDL associated tocopherol by an in vitro blood-brain barrier model. J. Neurochem. 89(4), 939-950 (2004).
70. Paternq̀ R, Ruocco A, Postiglione A, Hubsch A, Andresen I, Lang MG. Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke. Cerebrovasc. Dis. 17(2-3), 204-211 (2004).
71. Lapergue B, Moreno JA, Dang BQ et al. Protective effect of high-density lipoprotein-based therapy in a model of embolic stroke. Stroke 41(7), 1536-1542 (2010).
72. Drew BG, Duffy SJ, Formosa MF et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119, 2103-2111 (2009).
73. Drew BG, Carey AL, Natoli AK et al. Reconstituted high-density lipoprotein infusion modulates fatty acid metabolism in patients with type 2 diabetes mellitus. J. Lipid Res. 52(3), 572-581 (2011).
74. Calkin AC, Drew BG, Ono A et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 120, 2095-2104 (2009).
75. Ryan RO, Forte TM, Oda MN. Optimized bacterial expression of human apolipoprotein A-I. Protein Expr. Purif. 27(1), 98-103 (2003).
76. Banerjee S, Huber T, Sakmar TP. Rapidincorporationof functionalrhodopsin into nanoscale apolipoprotein bound bilayer (NABB) particles. J. Mol Biol. 377(4), 1067-1081 (2008
77. Hovingh GK, Bochem AE, Kastelein JJ. Apolipoprotein A-I mimetic peptides. Curr. Opin. Lipidol. 21(6), 481-486 (2010).
78. Yang M, Chen J, Cao W et al. Attenuation of nontargeted cell-kill using a high-density lipoprotein-mimicking peptide-phospholipid nanoscaffold. Nanomedicine (Lond.) 6(4), 631-641 (2011).
79. Anantharamaiah GM, Jones JL, Brouillette CG et al. Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J. Biol. Chem. 260(18), 10248-10255 (1985).
80. Zhang Z, Chen J, Ding L et al. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 6(3), 430-437 (2010).
81. Counsell RE, Pohland RC. Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents. J. Med. Chem. 25(10), 111-125 (1982)